An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs DCR PHXC (Primary)
- Indications Primary hyperoxaluria
- Focus Adverse reactions; Registrational
- Acronyms PHYOX 3
- Sponsors Dicerna Pharmaceuticals
- 07 Nov 2019 According to a Dicerna Pharmaceuticals media release, multi-dose data from this trial is expected in the first half of 2020.
- 08 Aug 2019 According to a Dicerna Pharmaceuticals media release, the company initiated dosing in this trial.
- 30 Jul 2019 Status changed from planning to recruiting.